• Welcome to the future...

    SCILEX Pharmaceuticals

    We are an emerging growth pharmaceutical company focused on acquiring and commercializing late stage prescription products with more efficient and effective delivery solutions for the treatment of pain.


Find out About Our Products and Pipeline

We are committed to excellence in everything we do, including helping our Company achieve its Mission and Vision.


Our mission is to develop and commercialize branded pharmaceutical products using innovative technologies that offer maximum value to patients.


Our vision is to become a world-class, global pharmaceutical company that delivers the next generation of innovative products. Leveraging our network of global relationships, we acquire high barrier-to-entry, late-stage products for development and commercialization.

SCILEX has created a strategic commercialization approach that captures competitive advantage by:

  • Specializing in the acquisition, late-stage clinical development, and sales/marketing of branded products for the treatment of pain
  • Focusing on high barrier-to-entry products such as transdermals (patch products), where we have demonstrated expertise
  • Leveraging an international network of manufacturers and product developers to access proprietary, best-in-class technologies that allow us to create next generation products with extended patent life.


Our values are at the heart of our corporate culture and the foundation for our partnerships. We strive to live by these values every day to make a positive impact on the world:

  • Respect
  • Diversity
  • Commitment to excellence
  • Ethical business practices
  • Quality
  • Accountability

These values are at the core of our successful collaborations and relationships with strategic partners through whom we are able to acquire, develop, and promote prescription medicines.


Meet Our Team of Experienced Veterans

SCILEX is led by a passionate team of industry veterans and visionary thinkers, committed to excellence and expansion through a collaborative approach and successful partnerships.

Our seasoned and driven executive team has the right experience to effectively acquire, develop, and commercialize.

  • Global expertise in sales, marketing, operations, business development, regulatory, finance, compliance, and legal
  • Successful clinical development and regulatory approval of multiple branded and generic products; our Board Member, Dr. Eric Floyd, has been involved with the regulatory approval of more than twenty branded products
  • Launch and management experience of more than fifteen branded and generic products, including seven branded products for the treatment of chronic and acute pain management
  • Marketing leadership for products that generated, in aggregate, in excess of $4 billion in sales annually
  • Demonstrated marketing, sales management, and sales training leadership for seven branded pain products.
  • Established relationships with KOLs in chronic pain management and acute pain management and post-op pain management since 1998.
  • Finance and operations experience involving drug products including management of gross to net revenues as well as being responsible for managing promotional budgets
  • Established trade relationships with key accounts such as wholesalers, distributors, and retailers



Anthony Mack

Co-Founder and CEO

William Pedranti

Co-Founder and COO


Explore Partnership Opportunities With Us

SCILEX’s business model is based upon building strong relationships with leading companies that innovate, manufacture, develop, market and sell novel products and technologies.

In addition, in order to effectively utilize our resources, the Company operates ‘virtually’ by bringing in leaders in the industry as consultants to assist the Company in various areas. The management team works with leading consultants including:

  • Ken Smith, Ph.D. (IP Counsel)
  • Beckloff Associates/Cardinal Health (cGMP Consultant)
  • Clinipace Worldwide (CRO, Regulatory)
  • Lowenstein Sandler, LLP (Outside Legal Counsel)
  • Chord Advisors (Financial Advisors)
  • BDO USA, LLP (Auditor)
  • David Rosen, Partner, Foley & Lardner (FDA counsel)

A business model focused on providing near-term returns and long-term growth.

At SCILEX, we’re future-focused and passionate about progress. We specialize in developing and commercializing late-stage pharmaceutical products for the treatment of pain.

As your partner, we will develop and commercialize pharmaceutical products using innovative technologies that offer maximum value to patients and help address unmet needs.

The SCILEX Business Strategy



Management team with a track record of success



Access to high barrier-to-entry medicines



Leveraging a global network